Article Text

PDF
Original Article
Chromoendoscopy versus narrow band imaging in UC: a prospective randomised controlled trial
  1. Raf Bisschops1,
  2. Talat Bessissow1,2,
  3. Joseph A Joseph2,
  4. Filip Baert3,
  5. Marc Ferrante1,
  6. Vera Ballet1,
  7. Hilde Willekens1,
  8. Ingrid Demedts1,
  9. Karel Geboes4,
  10. Gert De Hertogh4,
  11. Séverine Vermeire1,
  12. Paul Rutgeerts1,
  13. Gert Van Assche1
  1. 1Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Vlaams Brabant, Belgium
  2. 2Department of Gastroenterology, Royal Victoria Hospital, McGill University Health Center, Montreal, Canada
  3. 3Department of Gastroenterology, AZ Delta Roeselaere-Menen, Roeselaere, Belgium
  4. 4Department of Pathology, University Hospital Leuven, Leuven, Belgium
  1. Correspondence to Professor Raf Bisschops, Division of Gastroenterology, University Hospitals Leuven, KU Leuven, 49 Herestraat, 3000-Leuven, Belgium; raf.bisschops{at}uzleuven.be

Abstract

Background Patients with long-standing UC have an increased risk for the development of colonic neoplastic lesions. Chromoendoscopy (CE) has been proven to enhance neoplasia detection while the role of virtual chromoendoscopy (VC) is still to be defined.

Objective To compare the performance of CE to VC for the detection of neoplastic lesions in patients with long-standing UC.

Design A multicentre prospective randomised controlled trial. 131 patients with long-standing UC were randomised between CE with methylene blue 0.1% (n=66) or VC with narrow band imaging (NBI) (n=65). Biopsies were taken from visible lesions and surrounding mucosa. No random biopsies were performed. The primary outcome was the difference in total number of neoplastic lesions detected in each group.

Results There was no significant difference between NBI and CE for neoplasia detection. Mean number of neoplastic lesions per colonoscopy was 0.47 for CE and 0.32 for NBI (p=0.992). The neoplasia detection rate was not different between CE (21.2%) and NBI (21.5%) (OR 1.02 (95% CI 0.44 to 2.35, p=0.964). Biopsies from the surrounding mucosa yielded no diagnosis or dysplasia. The per lesion neoplasia detection was 17.4% for CE and 16.3% for NBI (OR 1.09 (95% CI 0.59 to 1.99, p=0.793). The total procedural time was on average 7 min shorter in the NBI group.

Conclusion CE and NBI do not differ significantly for detection of colitis-associated neoplasia. Given the longer withdrawal time for CE and easier applicability, NBI may possibly replace classical CE.

Trial registration number NCT01882205; Results.

  • Ulcerative colitis
  • dysplasia surveillance
  • chromo-endoscopy
  • narrow band imaging
  • DALM

Statistics from Altmetric.com

Footnotes

  • Contributors RB and TB participated in the study conception, patient recruitment, data collection, data analysis, writing of the manuscript and final approval of the manuscript. FB, MF, ID, SV, GV and PR participated in patient recruitment, data analysis, critical revision and approval of the final manuscript. VB and HW participated in patient recruitment and data collection. KG and GDH performed the pathological analysis, contributed to the writing and approval of the final manuscript. JAJ and MF participated in data analysis, writing of the manuscript and final approval of the manuscript.

  • Funding RB, MF and GVA are supported by a grant of Research Foundation – Flanders (FWO). RB has received a study grant from the Belgian Society of Gastrointestinal Endoscopy (BSGIE).

  • Competing interests RB has received speaker’s fee and research support from Olympus, not related to this trial.

  • Patient consent Obtained.

  • Ethics approval Ethics committee of UZ Leuven (ref nr ML4291), and the McGill University Health Centre (ref number 12-213-GEN).

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement The authors declare that their are no additional unpublished data from this study.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.